What do systematic reviews say?

Galantamine vs placebo

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1188 participants
  Moderate

Galantamine vs placebo

Galantamine leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 26 weeks compared with placebo (high certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.32 [1.03, 1.7]
  2 studies · 1326 participants
  High

Galantamine vs placebo

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1174 participants
  Low

Galantamine vs placebo

Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.57 [1.02, 2.43]
  2 studies · 1378 participants
  Moderate

Galantamine vs placebo

Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.12 [0.78, 1.59]
  1 study · 786 participants
  Moderate